Objective
=========

Studies on the association of HER-2/neu with the axillary lymph node metastasis are controversial. Amplification of the protein product of the HER-2/neu oncogene in primary breast cancer specimens is associated with an adverse prognosis.

Methods
=======

From January 2000 to December 2008, 504 breast cancer patients were operated on at General Hospital \'Sveti Vracevi\' in Bijeljina. We selected 253 (50.2%) patients with breast cancer who had metastases to axillary lymph nodes.

Results
=======

Extracapsular extension (ECM) was found in 103 (40.7%) patients. The patients were identified and divided into two groups: the HER-2-positive group (38 patients) and the HER-2-negative group (65 patients). In the HER-2-positive group ECM was seen in 62.5% of patients, compared with 37.4% in the HER-2-negative group (*P*= 0.059). The total number of lymph nodes showing ECM were also significantly more in the HER-2-positive group (48 out of 81, 59.25%), versus 13 out of 60 (21.66%) in the HER-2-negative group (*P*\< 0.001). With a median follow-up of 96 months, factors with independent prognostic value for disease-free survival by multivariate analysis included HER-2/neu overexpression with extracapsular extension (*P*\< 0.005), pN category (*P*\< 0.01), presence of lymphovascular invasion (*P*\< 0.005), and ECM (*P*\< 0.001). An independent negative prognostic effect on overall survival was observed for HER-2/neu overexpression with extracapsular extension (*P*\< 0.05), pN category (*P*\< 0.05), and presence of lymphovascular invasion (*P*\< 0.005) and ECM (*P*\< 0.001).

Conclusion
==========

In patients whose tumors expressed HER-2/neu who had positive lymph nodes and extracapsular extension, prognosis was significantly worse compared with those who were HER-2/neu-negative and lymph node-positive with extracapsular extension. These findings have led to the conclusion that HER-2/neu overexpression is associated with a more aggressive subtype of cancer.
